Medical malpractice case screening

Clarity Before Commitment.

A careful read of the records, so you know whether a case is worth pursuing before you commit.

Speak with the Founder

A 15-minute walkthrough, then demo access to run your own cases.

MedMalPal · Merit Review

Privileged & Confidential · Attorney Work Product

Sample Matter — Death from Ovarian Carcinoma; Delayed Pathologic Diagnosis

Likely a case

Very unlikelyProbably notCoin flipLikelyAlmost certain

Strongest point

The treating surgeon’s own note that a correct diagnosis would have prompted staging, debulking, and chemotherapy ties the misread directly to the untreated interval.

Weakest point

The carcinoma was platinum-refractory with adverse molecular features, so the defense can argue the outcome would have been the same even with earlier treatment.

Alleged injuryDeath due to cancer

Preliminary concernDelayed diagnosis of carcinoma

Record basis2,217 pages across 2 documents, read in full

I. Overall screening assessment

This potential claim presents meaningful merit and warrants serious further evaluation. The central issue — an invasive, poorly-differentiated ovarian carcinoma misclassified as a serous borderline tumor at the initial surgery — is supported by the later amended pathology, the concurrence of a subspecialty pathologist, and an outside second opinion. The treating surgeon’s own note that a correct diagnosis would have prompted staging, debulking, and adjuvant chemotherapy anchors both the standard-of-care deviation and its causal link to the untreated interval.

II. Injuries at issue

Progression to high-grade ovarian carcinoma, ultimately staged FIGO IVB with widespread metastatic disease.
Death of the patient, attributed to metastatic ovarian carcinoma following platinum-refractory disease.

III. Standard of care analysis

Issue 1 · Pathologic misclassification of the initial ovarian specimen

Plaintiff

The initial pathology classified the specimen as a borderline serous tumor — a diagnosis amended eleven months later to invasive poorly-differentiated carcinoma. A qualified pathologist may be expected to identify the invasive features on a permanent section reviewed over days, against a large complex mass, atypical washings, and a markedly elevated CA-125.

Defense

Distinguishing a borderline tumor from invasive carcinoma is a recognized diagnostic challenge, and the gross specimen and frozen section were macroscopically reassuring. The amendment came only on side-by-side comparison with a later specimen — retrospective pattern recognition, not proof the original reading fell below the standard of care.

IV. Causation analysis

Plaintiff

Ovarian-cancer survival is strongly stage-dependent; cytoreduction and adjuvant platinum chemotherapy at an earlier stage produce materially better outcomes. The patient was denied roughly ten months of treatment while the disease progressed from potentially resectable to widely metastatic.

Defense

The tumor’s aggressive biology — platinum-refractory after two cycles, with multiple adverse molecular features — carries a poor prognosis even when treated optimally and early. On this record, earlier treatment may not have altered the ultimate outcome.

V. Expert review recommendations

Gynecologic pathology — whether the original specimen should have been read as invasive.
Gynecologic oncology — the effect of the delay on staging, treatment, and survival.

Additional records to obtain

The original pathology slides and blocks, for independent re-review.

Illustrative preview · not an actual case

Direction for the next stepGrounded in the recordBoth perspectivesMissing records flagged

Why it’s different

Built by a medical malpractice attorney.

MedMalPal was built by Brad Walkon, a practicing med-mal attorney, for the decision he faces on every intake: is this case worth the firm’s time and money?

It reads a chart the way a plaintiff’s attorney does, not the way a general document tool does. And it has no stake in the answer, so it will tell you when to walk away.

Brad Walkon · Partner, Walkon Law Firm

Heather Baker DobbsMedical Malpractice Attorney
Ikuta Hemesath Leonard LLP

One upload. Two tools.

Screen the case with the Merit Review, then interrogate it with Ask Pal. Every conclusion anchored to the record.

MedMalPal · Merit Review

Privileged & Confidential · Attorney Work Product

Sample Matter — Death from Ovarian Carcinoma; Delayed Pathologic Diagnosis

Likely a case

Very unlikelyProbably notCoin flipLikelyAlmost certain

Strongest point

The treating surgeon’s own note that a correct diagnosis would have prompted staging, debulking, and chemotherapy ties the misread directly to the untreated interval.

Weakest point

The carcinoma was platinum-refractory with adverse molecular features, so the defense can argue the outcome would have been the same even with earlier treatment.

Alleged injuryDeath due to cancer

Preliminary concernDelayed diagnosis of carcinoma

Record basis2,217 pages across 2 documents, read in full

I. Overall screening assessment

II. Injuries at issue

Progression to high-grade ovarian carcinoma, ultimately staged FIGO IVB with widespread metastatic disease.
Death of the patient, attributed to metastatic ovarian carcinoma following platinum-refractory disease.

III. Standard of care analysis

Issue 1 · Pathologic misclassification of the initial ovarian specimen

Plaintiff

Defense

IV. Causation analysis

Plaintiff

Defense

V. Expert review recommendations

Gynecologic pathology — whether the original specimen should have been read as invasive.
Gynecologic oncology — the effect of the delay on staging, treatment, and survival.

Additional records to obtain

The original pathology slides and blocks, for independent re-review.

Illustrative preview · not an actual case

The Merit Review. Standard of care, causation, the damages picture, the facts that cut both ways, and what the record is missing, with a clear read on strength.

MedMalPal · Ask Pal

Interrogate the case

Pal answers from the records it reviewed — and cites the source file and page.

Steelman the defense on standard of care.

The defense’s strongest standard-of-care position is that this was a genuinely close diagnostic call. On the initial specimen, the gross and frozen-section findings were consistent with a borderline serous tumor (Sample Doc 1, p.14), and separating a borderline tumor from early invasive carcinoma is a recognized challenge on which competent pathologists disagree. The invasive focus surfaced only on the amended read, after side-by-side comparison with the later specimen (Sample Doc 2, p.3) — retrospective pattern recognition, not proof the original interpretation breached the standard. A defense expert can credibly testify that a reasonable pathologist could have read the same slide the same way in real time.

Restate this case in one sentence.

A woman’s invasive ovarian carcinoma was misread as a borderline tumor at her initial surgery and left uncorrected for eleven months (Sample Doc 1, p.14), and the case turns on whether that delay — rather than the tumor’s aggressive, ultimately platinum-refractory biology — changed her outcome.

Ask Pal about this case…Ask

Illustrative preview · not an actual case

Ask Pal. Question the records directly, cited to the page, weighing both sides, so you can press a theory before you commit.

Built only for medical malpractice.

Not a general litigation platform pointed at medical records. MedMalPal reads the whole chart, then keys its analysis to the issues that decide a med-mal case.

Generic AI	MedMalPal
Summarizes what happened	Evaluates why it matters
Often masks uncertainty	Surfaces uncertainty and competing explanations
Tells you what you asked	Tells you what the records support, including when to pass
Built for everything	Built only for medical malpractice

The MedMalPal Standard

Complete Review

Every page is evaluated before any conclusion is drawn.

Record-Grounded

Every conclusion is anchored to the medical record.

Independent

No stake in the outcome. We sell no experts. When a case is weak, it says so.

Attorney Judgment

The final decision always belongs to the attorney.

Security & Confidentiality

Designed around HIPAA’s security safeguards. We keep only what is needed, encrypt it, and put the retention window in your hands.

AES-256 encrypted, in transit and at rest
Firm-only access
Never training data, never sold
Auto-deleted after your retention window

See our Privacy Policy for the details.

Clarity Before Commitment.

See a Merit Review walked through on a real case, then run MedMalPal on your own.

Speak with the Founder